I-Mab (NASDAQ:BDTX) Insider Brent Hatzis-Schoch Sells 4,078 Shares

I-Mab (NASDAQ:BDTX) insider Brent Hatzis-Schoch sold 4,078 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $31.04, for a total value of $126,581.12. Following the completion of the sale, the insider now owns 7,078 shares of the company’s stock, valued at $219,701.12. The sale was disclosed in a filing with the SEC, which is available at this link.

BDTX traded up $0.79 on Wednesday, reaching $29.93. The company’s stock had a trading volume of 330,307 shares, compared to its average volume of 191,755. I-Mab has a 1 year low of $17.63 and a 1 year high of $46.25. The business’s 50 day moving average is $29.49 and its 200 day moving average is $32.52. The stock has a market cap of $1.07 billion and a price-to-earnings ratio of -1.77.

I-Mab (NASDAQ:BDTX) last released its earnings results on Tuesday, August 11th. The company reported ($0.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.03. Research analysts anticipate that I-Mab will post -2.11 earnings per share for the current year.

Several brokerages have recently weighed in on BDTX. Zacks Investment Research raised I-Mab from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Wednesday, August 12th. BidaskClub upgraded I-Mab from a “strong sell” rating to a “sell” rating in a report on Wednesday. Canaccord Genuity reaffirmed a “buy” rating and issued a $50.00 price objective on shares of I-Mab in a research report on Thursday, May 21st. Finally, HC Wainwright reissued a “buy” rating and set a $53.00 target price on shares of I-Mab in a research report on Wednesday, August 12th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. I-Mab has an average rating of “Buy” and a consensus price target of $45.60.

About I-Mab

Black Diamond Therapeutics, Inc, a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.

See Also: Fibonacci Channel

Insider Buying and Selling by Quarter for I-Mab (NASDAQ:BDTX)

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.